PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Anqing Medical Co., Ltd.

USPTO PatentsView assignee record - 5 granted patents across 1 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Anqing ranks #44,736 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 1 technology areas.

#44,736
of 49,997 US assignees by volume
40th percentile
by Innovation Score (32.2/100)
15.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R44736 · Foreign Corporation #44,736 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • LOWER-Q #44,736/49,997
  • PHOTO-FINISH Anixa Diagnostics
  • CPC-NARROW A61B · 1 areas
  • INNOV-THIN 32.2/100
  • CLAIMS-RICH 15.2 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2023–2025 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Anixa Diagnostics Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Anqing’s 32.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Anqing

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Anqing's Innovation Score is 32.2/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Anqing?

Each dot is one of Anqing’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Anqing’s own 15.2 claims/patent is at or below the 15.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Anqing vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 010203040 Granted patents (volume) Avg claims / patent Anixa Diagnostics Corporation - 5, 30.8Anixa DiagnosticsAnkom Technology Corporation - 5, 18.2Ankom TechnologyAnomera Inc. - 5, 21.4AnomeraAnovent Pharmaceutical (U.S.), LLC - 5, 15.4Anovent Pharmaceu…Ansaldo Energia S.P.A. - 5, 12.8Ansaldo Energia S…Antares Vision S.p.A. - 5, 10.4Antares Vision S…Antenna Company - 5, 2.4AntennaAntepes, LLC - 5, 17.2AntepesAnqing Medical Co., Ltd. - 5, 15.2Anqing Medical
Anqing vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Anqing's grants concentrate

Anqing Medical Co., Ltd. is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, Anqing sits between Anixa Diagnostics Corporation and Antepes, LLC.

Anqing's three-year grant acceleration

Anqing Medical Co., Ltd. shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Anqing's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Anqing holds 5 patents at rank #44,561, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Anqing

By rank, the assignees closest to #44,561 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Anqing's primary technology class.

Anqing's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1.522.533.5 20232025 3
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
Anqing Medical Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 2 40.0%
2025partial year 3 60.0%

Which technologies does Anqing Medical Co., Ltd. patent most?

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Anqing Medical Co., Ltd.'s patent record in context - here's where to go next.

  • Anqing Medical Co., Ltd.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #44,736 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Anqing Medical Co., Ltd. against Anixa Diagnostics Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 32.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.